Mizuho analyst Dan Dolev lowered the firm’s price target on ADP to $275 from $285 and keeps a Buy rating on the shares. While the company’s results in ES continued to be strong, the slowdown in PEO weighed on the stock, the analyst tells investors in a research note. The firm’s research suggests that this is neither driven by macro weakness nor is it reflective of execution issues. The slowdown was mostly due to an above-average drag from medical benefits price increases, contends Mizuho.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ADP: